Trial record 1 of 1 for:    NCT00235443
Previous Study | Return to List | Next Study

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00235443
First received: October 6, 2005
Last updated: September 19, 2011
Last verified: September 2011

October 6, 2005
September 19, 2011
September 2004
July 2008   (final data collection date for primary outcome measure)
Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator. [ Time Frame: Throughout the study up to a maximum study period of 2.8 years ] [ Designated as safety issue: No ]
Number of subjects with adverse events (AEs) reported spontaneously by the subject or observed by the investigator (serious and non-serious).
Not Provided
Complete list of historical versions of study NCT00235443 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Average Daily Pain Score Using an 11-point Likert Scale (0-10). [ Time Frame: Baseline to end of entire treatment phase (maximum study period of 2.8 years). ] [ Designated as safety issue: No ]
    Change from Baseline in average daily pain score using an 11-point Likert scale (0-10). On Likert scale, 0=no pain and 10=worst possible pain.
  • Change From Baseline in Average Pain Score as Measured by a 100mm Visual Analogue Scale (VAS). [ Time Frame: Baseline to end of entire treatment phase (maximum study period of 2.8 years). ] [ Designated as safety issue: No ]
    Change from Baseline in average pain score as measured by a 100mm Visual Analogue Scale (VAS). On VAS 0mm=no pain and 100mm=worst possible pain.
  • Patient's Global Impression of Change (PGIC) From Baseline in Pain. [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Patient's Global Impression of Change (PGIC) from Baseline in Pain. Original categorical responses are much worse, moderately worse, mildly worst, no change, mildly better, moderately better, and much better. Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity. [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for intensity of pain where 0=no pain and 10=most intense pain sensation imaginable.
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) for sharpness of pain where 0=not sharp and 10=most sharp sensation imaginable ("like a knife").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with heat sensation where 0=not hot and 10=the most hot sensation imaginable ("on fire").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with dullness of pain where 0=not dull and 10=most dull sensation imaginable.
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with cold sensation where 0=not cold and 10=most cold sensation imaginable ("freezing").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with sensitivity of pain where 0=not sensitive and 10=most sensitive sensation imaginable ("raw skin").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with itchiness where 0=not itchy and 10=most itchy sensation imaginable ("like poison oak").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with unpleasantness where 0=not pleasant and 10=most unpleasant sensation imaginable ("intolerable").
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with deep pain where 0=no deep pain and 10=most intense deep pain sensation imaginable.
  • Within-subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Within-subject change in neuropathic pain using the Neuropathic Pain Scale (NPS) with surface pain where 0=no surface pain and 10=most intense surface pain imaginable.
  • Change From Baseline in Average Pain Interference With Sleep (11-point Likert Scale) [ Time Frame: Baseline to end of entire treatment phase visit ] [ Designated as safety issue: No ]
    Change from Baseline in average pain interference with sleep (11-point Likert scale) where 0=no interference with sleep and 10=worst possible interference with sleep.
  • Change From Baseline in Average Pain Interference With Activity (11-point Likert Scale) [ Time Frame: Baseline to end of entire treatment phase visit ] [ Designated as safety issue: No ]
    Change from Baseline in average pain interference with activity (11-point Likert scale) where 0=no interfence with activity and 10=worst possible interference with activity.
  • Change From Baseline in Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Change from Baseline in quality of life using the SF-36 Health Survey - Physical Component Summary (PCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.
  • Change From Baseline in Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) [ Time Frame: Baseline to Termination Visit ] [ Designated as safety issue: No ]
    Change from Baseline in quality of life using the SF-36 Health Survey - Mental Component Summary (MCS). Values range from 0 to 100 with high values indicating a good condition. Positive change in baseline values indicate improvement in quality of life.
Not Provided
Not Provided
Not Provided
 
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
A Multi-Center, Open-Label, Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Phase 2/3 open-label trial to assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in subjects with painful diabetic neuropathy. The safety and tolerability of the different doses of lacosamide will be investigated.

This phase 2/3 open-label trial is being conducted at approximately 100 sites in the US to assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in subjects with painful diabetic neuropathy. Approximately 525 subjects will be enrolled. To qualify for this trial, subjects with symptoms of painful distal diabetic neuropathy ranging in duration from 6 months to 5 years must have completed trials SP665, SP742, or SP768 and, in the investigator's opinion, may benefit from long-term administration of lacosamide. Subjects will be titrated to their optimal dose of lacosamide (up to 600mg/day). The safety and tolerability of the different doses of lacosamide will be investigated throughout the trial. In addition, to determine what effect lacosamide has on diabetic neuropathic pain, subjects will use a diary to record their daily pain intensity and pain interference with sleep and activity. Subjects' quality of life will also be investigated.

Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetic Neuropathy
Drug: lacosamide
Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
Other Name: SPM927
Experimental: 1
Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
Intervention: Drug: lacosamide
Shaibani A, Biton V, Rauck R, Koch B, Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur J Pain. 2009 May;13(5):458-63. Epub 2008 Jul 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
451
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who completed Study SP665, SP742, or SP768 and, in the investigators opinion, might benefit from long-term administration of SPM 927. Exception: subjects who prematurely discontinued Study SP742 or SP768 due to lack of efficacy or due to intolerability to trial medication may be eligible to participate in Study SP745, after consultation with the medical monitor.

Exclusion Criteria:

  • Subject has clinically relevant electrocardiogram (ECG) abnormalities, or QT-corrected (QTc) interval >=500 milliseconds (ms), and/or a QTc interval increase of >=60ms from the mean pre-dose QTc value at Visit 2 of Studies SP665, SP742 or SP768.
  • Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >=3 times the upper limit of the normal range (ULN) with total bilirubin >=2 times ULN or transaminases (AST and/or ALT) >=5 times ULN.
  • Subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial.
Both
32 Years to 81 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00235443
SP745
No
UCB Pharma
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB Pharma
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP